CJC-1295 vs Ipamorelin: Key Differences & Research Comparison
Growth hormone research is one of the most active areas in peptide science right now. And if you’re working in this space, two names come up constantly — CJC-1295 and Ipamorelin.
They’re often mentioned together, sometimes sold as a blend, and frequently compared. That makes sense. Both are growth hormone secretagogues — peptides studied for their ability to stimulate GH release from the pituitary gland. Both show up in similar research contexts.
But here’s what a lot of comparisons get wrong: CJC-1295 and Ipamorelin are not two versions of the same thing. They work through entirely different receptor pathways, produce different patterns of GH release, and suit different experimental designs.
Understanding what actually separates them is what this guide is about.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the endogenous 44-amino acid neuropeptide produced in the hypothalamus that tells the pituitary gland to release growth hormone.
The naturally occurring GHRH breaks down quickly in the bloodstream, degraded by an enzyme called DPP-IV (dipeptidyl peptidase IV). CJC-1295 was engineered to resist this enzymatic breakdown through specific amino acid substitutions, making it more stable in laboratory conditions and giving it a longer window of activity.
There are two main forms of CJC-1295 that appear in research:
CJC-1295 with DAC (Drug Affinity Complex): The DAC modification allows the peptide to bind to albumin — the most abundant protein in blood — which dramatically extends its half-life to several days. This creates sustained, continuous GH signaling rather than discrete pulses.
CJC-1295 without DAC (also called Mod GRF 1-29 or Modified GRF 1-29): Without the albumin-binding modification, the peptide has a half-life of approximately 30 minutes. This produces pulsatile GH release that more closely mirrors the body’s natural rhythms.
Most research combining CJC-1295 with Ipamorelin uses the no-DAC version, because pulsatile release is considered closer to physiological GH patterns and reduces the risk of receptor desensitization.
Quick specs:
- Amino acids: 29–30
- Molecular weight (no DAC): ~3,647 Da
- Half-life: ~30 minutes (no DAC) / several days (with DAC)
- Receptor target: GHRH receptor (GHRH-R) on pituitary somatotroph cells
- Primary research focus: Sustained or pulsatile GH signaling, IGF-1 elevation, pituitary axis studies
What Is Ipamorelin?
Ipamorelin (research identifier NNC 26-0161) is a synthetic pentapeptide — five amino acids — developed by Novo Nordisk in the late 1990s. It belongs to a class called growth hormone secretagogues (GHS), and it works through a completely different receptor than CJC-1295.
Rather than mimicking GHRH, Ipamorelin mimics ghrelin — often called the hunger hormone — and activates the ghrelin receptor, formally known as GHS-R1a (growth hormone secretagogue receptor type 1a). Ghrelin receptors are found in the pituitary, but also in the brain, gastrointestinal tract, and other tissues.
What makes Ipamorelin stand out among older GHRPs (growth hormone-releasing peptides) is its selectivity. Earlier peptides in the same class — like GHRP-2 and GHRP-6 — stimulated GH release but also significantly elevated cortisol and prolactin levels, which limited their usefulness in precise research protocols.
Ipamorelin is far more selective. It produces GH pulses with minimal effect on cortisol or prolactin, making it a cleaner tool for studying GH-axis signaling without unwanted hormonal interference.
It also does something CJC-1295 doesn’t: it suppresses somatostatin — the body’s “off switch” for GH release. By removing the inhibitory brake on GH release at the same time it activates the pituitary, Ipamorelin can produce stronger GH pulses than CJC-1295 alone achieves.
Quick specs:
- Amino acids: 5
- Sequence: Aib-His-D-2Nal-D-Phe-Lys
- Molecular weight: ~712 Da
- Half-life: ~2 hours
- Receptor target: GHS-R1a (ghrelin receptor) on pituitary somatotroph cells
- Primary research focus: Selective pulsatile GH release, ghrelin receptor studies, GH axis research
CJC-1295 vs Ipamorelin: Head-to-Head Comparison
| Feature | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Amino acids | 29–30 | 5 |
| Molecular weight | ~3,647 Da | ~712 Da |
| Receptor target | GHRH receptor (GHRH-R) | Ghrelin receptor (GHS-R1a) |
| Mechanism | GHRH pathway — signals pituitary to produce GH | Ghrelin pathway — activates pituitary GH release + suppresses somatostatin |
| GH release pattern | Pulsatile (no DAC) / Sustained (with DAC) | Short, sharp pulses (~2 hours) |
| Half-life | ~30 min (no DAC) / days (with DAC) | ~2 hours |
| Effect on cortisol | Minimal | Minimal (key advantage over older GHRPs) |
| Effect on prolactin | Minimal | Minimal |
| Somatostatin suppression | No | Yes |
| IGF-1 elevation | Yes — significant (up to 50–200% in studies) | Yes — indirect via GH |
| Research generation | GHRH analog | Third-generation GHRP |
| Form | Lyophilized powder | Lyophilized powder |
The Growth Hormone Axis — Why Two Different Receptors Matter
To understand why CJC-1295 and Ipamorelin are studied together, you need to understand how the GH axis actually works.
The hypothalamus sends two opposing signals to the pituitary:
- GHRH (growth hormone-releasing hormone) — the “on” signal, tells the pituitary to release GH
- Somatostatin — the “off” signal, suppresses GH release
GH is released in pulses — naturally, primarily during deep sleep and after intense exercise — as a result of this push-and-pull system.
CJC-1295 hits the “on” signal side. It binds to GHRH receptors and tells the pituitary to produce more GH — mimicking what the hypothalamus does naturally but with greater stability and duration.
Ipamorelin hits the ghrelin pathway — a separate route to GH release that also suppresses somatostatin, effectively reducing the “off” signal at the same time.
What this means in research terms: when you use both together, you’re stimulating GH release through two independent receptor systems simultaneously, while also reducing the inhibitory signal that would normally limit the response. The result is a stronger, more physiological GH pulse than either peptide produces on its own — which is exactly why the combination is so commonly studied.
How Each Peptide Works in Detail
CJC-1295: The GHRH Pathway
CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary. This activates adenylyl cyclase, increases intracellular cAMP, and ultimately triggers GH synthesis and secretion.
Human studies have shown significant effects:
- A dose of 60 mcg/kg resulted in approximately a 150% increase in mean GH levels
- A dose of 250 mcg/kg produced a ~300% increase in 24-hour mean GH
- A single CJC-1295 injection elevated IGF-1 by 44–50% (Ionescu et al., 2006; Teichman et al., 2006), with effects lasting up to 10 days for the DAC version
The no-DAC version clears quickly (~30 minutes), creating a sharp GH pulse that maintains pituitary sensitivity — important for research protocols where receptor desensitization would compromise results.
Ipamorelin: The Ghrelin Pathway
Ipamorelin activates GHS-R1a receptors through a G-protein coupled mechanism distinct from the GHRH pathway. It also actively suppresses somatostatin release, which removes the primary inhibitory brake on GH secretion.
Research data:
- A single dose of 100 mcg/kg body weight significantly elevated GH, with peaks reaching around 80 mIU/L (~26.6 ng/mL)
- Significant GH elevation was also observed at much lower doses (10 mcg/kg)
- Cortisol and prolactin remained essentially unchanged — a key differentiator from older GHRPs
Because it produces sharp, short pulses (~2 hours), Ipamorelin is particularly useful for research protocols requiring controlled, timed GH release events.
Research Applications: What Each Is Studied For
CJC-1295 Research Focus
Sustained GH signaling studies The DAC version is used in research designs where prolonged GH elevation is the variable being studied — examining what happens to downstream markers like IGF-1 when GH remains elevated for days rather than hours.
Pituitary function and GHRH pathway studies Because CJC-1295 binds specifically to GHRH-R, which is largely restricted to the anterior pituitary, it’s a precise tool for isolating pituitary-driven GH signaling without the broader receptor cross-activation that ghrelin pathway agonists can produce.
IGF-1 elevation research CJC-1295 consistently elevates IGF-1 in research models, making it relevant for studies examining the downstream mediators of GH action — particularly body composition, cellular repair, and protein synthesis pathways.
Sleep and circadian rhythm research GHRH is naturally involved in regulating slow-wave sleep. Studies since the 1990s have shown that higher GHRH activity is associated with deeper, more restorative sleep stages. CJC-1295 features in research examining this relationship.
Ipamorelin Research Focus
Selective GH pulse modeling Ipamorelin’s selectivity makes it uniquely valuable for research that requires clean GH pulses without hormonal noise from cortisol or prolactin elevation. It’s considered the most selective GHRP available for this purpose.
Ghrelin receptor distribution studies Ghrelin receptors (GHS-R1a) are found not just in the pituitary, but in the brain, GI tract, and other tissues. Ipamorelin is used as a research tool to probe GHS-R function and distribution across these tissues.
Gastrointestinal motility research Ipamorelin was originally developed to improve gastrointestinal peristalsis — the wave-like contractions that move food through the digestive system. It features in GI motility research as a result of this early development history.
Somatostatin suppression studies The fact that Ipamorelin suppresses somatostatin makes it a useful probe for understanding the inhibitory regulation of GH release — particularly in research examining how somatostatin tone affects GH pulsatility.
CJC-1295 vs Ipamorelin: Which Produces Better Research Results?
This is the question researchers most commonly ask — and it misframes the issue.
The more useful question is: what pattern of GH release does your research protocol require?
CJC-1295 (no DAC) is better when:
- The protocol requires a pulsatile GH response that mirrors natural physiological patterns
- Prolonged receptor engagement needs to be avoided (to prevent desensitization)
- IGF-1 elevation over a multi-day window is relevant to the study design
- The research is specifically examining GHRH pathway signaling
- Timing and dosing flexibility are experimental variables
Ipamorelin is better when:
- Short, discrete, precisely timed GH pulses are required
- Cortisol and prolactin elevation would confound the results
- Ghrelin receptor biology is part of what’s being studied
- GI motility is a relevant experimental endpoint
- Somatostatin suppression is the variable of interest
Use both together when:
- Maximum GH pulse amplitude is the goal
- The research examines synergistic receptor pathway activation
- The protocol is designed around dual-pathway GH stimulation
- Studying the additive or synergistic effects of GHRH + ghrelin receptor co-activation
Why Researchers Use CJC-1295 and Ipamorelin Together
The combination of CJC-1295 (no DAC) and Ipamorelin is one of the most studied peptide stacks in GH research — and the rationale is mechanistically sound, not just empirical.
The synergy works on three levels:
Level 1 — Dual receptor activation: CJC-1295 activates GHRH receptors. Ipamorelin activates ghrelin receptors. These are entirely separate pathways — they’re not redundant. Activating both simultaneously produces a GH response that’s genuinely synergistic, not just additive.
Level 2 — Push and pull on somatostatin: CJC-1295 pushes the pituitary to release GH. Ipamorelin simultaneously suppresses somatostatin — the hormone that would otherwise limit that release. The result is a stronger, more complete GH pulse.
Level 3 — Complementary timing: Both peptides have relatively short half-lives in their research-grade forms, which means they work together in the same time window and produce a pulse that’s then cleared — preserving the natural pulsatile rhythm and reducing the risk of pituitary desensitization over repeated administrations.
CJC-1295 DAC vs No DAC — What’s the Actual Difference?
This is a common point of confusion that’s worth clarifying directly.
CJC-1295 with DAC:
- Half-life: Several days (up to a week)
- GH release pattern: Sustained, continuous elevation
- Dosing frequency: Less frequent (once or twice weekly in research)
- Primary use: Studies requiring prolonged GH elevation
- Concern: Risk of pituitary desensitization with chronic use; less physiological
CJC-1295 without DAC (Mod GRF 1-29):
- Half-life: ~30 minutes
- GH release pattern: Sharp pulse, then rapid clearance
- Dosing frequency: More frequent (matched to research protocol timing)
- Primary use: Studies requiring pulsatile, physiological GH release patterns
- Advantage: Preserves natural feedback mechanisms; preferred for combination protocols with Ipamorelin
For most CJC-1295 + Ipamorelin combination research, the no-DAC version is standard because the goal is to amplify natural pulsatile GH release — not to create sustained, non-physiological elevation.
Storage and Handling
Both CJC-1295 and Ipamorelin are supplied as lyophilized (freeze-dried) powder for research use.
Storage guidelines:
- Unopened vials: Store at -20°C for long-term stability (up to 24 months)
- Reconstituted solutions: Store at 2–8°C and use within 28–30 days
- Reconstitute with bacteriostatic water — not regular sterile water — to extend the stability of reconstituted solutions
- Protect from direct light and heat at all stages
- Avoid repeated freeze-thaw cycles once reconstituted
Both peptides should be handled under standard laboratory aseptic technique protocols. For complete reconstitution guidance, see our peptide storage and handling guide.
Frequently Asked Questions
What is the main difference between CJC-1295 and Ipamorelin? CJC-1295 is a GHRH analog — it activates GHRH receptors on the pituitary to stimulate GH production, producing either pulsatile (no DAC) or sustained (with DAC) GH elevation. Ipamorelin is a selective ghrelin receptor agonist — it activates a completely separate receptor pathway to trigger sharp GH pulses, while also suppressing somatostatin, the hormone that inhibits GH release. Same broad goal, completely different mechanisms.
Why are CJC-1295 and Ipamorelin often used together in research? Because their mechanisms are complementary, not redundant. CJC-1295 activates GHRH receptors; Ipamorelin activates ghrelin receptors and suppresses somatostatin. Combining them hits both the “on” signals for GH release from two independent angles, while simultaneously reducing the “off” signal — producing a stronger, more complete GH pulse than either achieves alone.
What is DAC in CJC-1295, and does it matter? DAC stands for Drug Affinity Complex — a modification that allows CJC-1295 to bind to albumin in the bloodstream, dramatically extending its half-life from ~30 minutes to several days. The DAC version creates sustained GH elevation; the no-DAC version creates pulsatile release. For combination research with Ipamorelin, the no-DAC version is standard because pulsatile release better mirrors natural physiological patterns.
Does Ipamorelin affect cortisol or prolactin levels? This is one of Ipamorelin’s key advantages over older GHRPs. Unlike GHRP-2 and GHRP-6, Ipamorelin produces GH pulses with minimal impact on cortisol or prolactin — making it a cleaner research tool for studies where hormonal interference would confound results.
Which is more commonly studied — CJC-1295 or Ipamorelin? Both appear extensively in the literature. CJC-1295 features more in sustained GH signaling and IGF-1 research. Ipamorelin is more prominent in selective GH pulse modeling and ghrelin receptor studies. Their combination is among the most studied peptide stacks in growth hormone research.
What is the half-life of each peptide? CJC-1295 without DAC has a half-life of approximately 30 minutes. CJC-1295 with DAC extends this to several days. Ipamorelin has a half-life of approximately 2 hours.
Are CJC-1295 and Ipamorelin available from Patriot Peptides? Yes. Both CJC-1295 and Ipamorelin are available in our research peptide catalog — manufactured in the USA, cGMP-certified, and independently third-party tested with verifiable Certificates of Analysis. For research use only.
Final Thoughts
CJC-1295 and Ipamorelin are not competing peptides — they’re complementary tools for studying growth hormone regulation from two different receptor angles.
CJC-1295 gives researchers control over the GHRH pathway — whether they want sustained elevation (DAC version) or physiological pulsatile release (no-DAC version). Ipamorelin gives researchers a selective, clean ghrelin receptor agonist that produces sharp GH pulses without hormonal noise.
Used together, they produce a GH stimulus that’s both stronger and more physiologically accurate than either peptide achieves independently — which is why the combination has become a standard reference protocol in growth hormone research.
Choose based on what your study is actually asking. Then use compounds you can trust — with verified purity, batch-specific COAs, and transparent testing from independent laboratories.
All products are strictly for laboratory research use only. Not for human consumption or veterinary use.
Explore our full research peptide catalog: CJC-1295 | Ipamorelin | Special Blends | Are research peptides legal in the USA.